Home » USA Broker Ratings » Insulet Corporation – Consenus Indicates Potential -9.6% Downside

Insulet Corporation – Consenus Indicates Potential -9.6% Downside

Insulet Corporation with ticker code (PODD) now have 14 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 185 and 125 with the average target price sitting at 160.57. Given that the stocks previous close was at 177.61 this now indicates there is a potential downside of -9.6%. The day 50 moving average is 156.83 and the 200 day moving average is 134. The company has a market capitalisation of $10,954m. You can visit the company’s website by visiting: http://www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn